Expression of fusion IL2-B7.1(IgV+C) and effects on T lymphocytes

Biochemistry and Cell Biology

Volumn 85, Issue 6, 2007, Pages 685-695

  Kong, Linghong ^a   Li, Yaochen ^b   Yang, Ye ^c   Li, Kangsheng ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

B7.1(IgV+C); Computer simulation; Costimulatory molecule; Fusion protein; IL2; T lymphocyte proliferation assay

Indexed keywords

COSTIMULATORY MOLECULES; FUSION PROTEINS; LYMPHOCYTE PROLIFERATION ASSAYS; LYMPHOCYTES;

COMPUTER SIMULATION; COMPUTER SOFTWARE; DNA; HYDROPHILICITY; ONCOLOGY; TUMORS;

PROTEINS;

EPITOPE; HYBRID PROTEIN; IMMUNOGLOBULIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B7.1; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY IL2; PROTEIN IL2 B7.1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; COMPUTER PROGRAM; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HYDROPHILICITY; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; POLYMERASE CHAIN REACTION; PROKARYOTE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN VARIANT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD80; CELL PROLIFERATION; CLONING, MOLECULAR; COMPUTATIONAL BIOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, AGAR GEL; EPITOPES; HUMANS; HYDROPHOBICITY; INTERLEUKIN-2; MICE; PLASMIDS; PLIABILITY; PROKARYOTIC CELLS; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

PROKARYOTA;

EID: 38849192306     PISSN: 08298211     EISSN: None     Source Type: Journal    
DOI: 10.1139/O07-136     Document Type: Article

References (25)

1. Beverly, B., Kang, S.M., Lenardo, M.J., and Schwartz, R.H. 1992. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int. Immunol. 4: 661-671. doi:10.1093/intimm/4.6.661.
2. Boon, T., Cerottini, J.C., Van den Eynde, B., van der Bruggen, P., and Van Pel, A. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337-365. doi:10.1146/annurev.iy.12.040194.002005.
3. Brenner, M.K. 2001. Gene transfer and the treatment of haematological malignancy. J. Intern. Med. 249: 345-358. doi:10.1046/j.1365-2796.2001. 00807.x.
4. Chan, L., Hardwick, N., Darling, D., Galea-Lauri, J., Gaken, J., Devereux, S., et al. 2005. IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Mol. Ther. 11: 120-131. doi:10.1016/j.ymthe.2004.09.006.
5. DelÕage, G. and Roux, B. 1987. An algorithm for protein secondary structure prediction based on class prediction. Prot Eng. 1: 289-294.
6. Fearon, E.R., Pardoll, D.M., Itaya, T., Golumbek, P., Levitsky, H.I., Simons, J.W., et al. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 60: 397-403. doi:10.1016/0092-8674(90)90591-2.
7. Finney, H.M., Akbar, A.N., and Lawson, A.D.G. 2004. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J. Immunol. 172: 104-113.
8. Gilboa, E. 1996. Immunotherapy of cancer with genetically modified tumor vaccines. Semin. Oncol. 23: 101-107.
9. Golumbek, P.T., Lazenby, A.J., Levitsky, H.I., Jaffee, L.M., Karasuyama, H., Baker, M., and Pardoll, D.M. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science, 254: 713-716. doi:10.1126/science.1948050.
10. Greenberg, P.D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49: 281-355.
11. Hock, H., Dorsch, M., Diamantstein, T., and Blankenstein, T. 1991. Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J. Exp. Med. 174: 1291-1298. doi:10.1084/jem.174.6.1291.
12. Houghton, A.N. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180: 1-4. doi:10.1084/jem.180.1.1.
13. Jenkins, M.K., and Schwartz, R.H. 1987. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165: 302-319. doi:10.1084/jem.165.2. 302.
14. Lamb, J.R., and Feldmann, M. 1984. Essential requirement for major histocompatibility complex recognition in T-cell tolerance induction. Nature, 308: 72-74. doi:10.1038/308072a0.
15. Martin-Fontecha, A., Moro, M., Crosti, M.C., Veglia, F., Casorati, G., and Dellabona, P. 2000. Vaccination with mouse mammary adenocarcinoma cells coexpressing B7-1 (CD80) and B7-2 (CD86) discloses the dominant effect of B7-1 in the induction of antitumor immunity. J. Immunol. 164: 698-704.
16. McAdam, A.J., Schweitzer, A.N., and Sharpe, A. 1998. The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol. Rev. 165: 231-247. doi:10.1111/j.1600-065X.1998.tb01242.x.
17. McAdam, A.J., Gewurz, B.E., Farkash, E.A., and Sharpe, A.H. 2000. Either B7 costimulation or IL-2 can elicit generation of primary alloreactive CTL. J. Immunol. 165: 3088-3093.
18. Melero, I., Mazzolini, G., Narvaiza, I., Qian, C., Chen, L., and Prieto, J. 2001. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol. 22: 113-115. doi:10.1016/S1471-4906(00)01824-X.
19. Rosenberg, S.A. 2001. Progress in human tumour immunology and immunotherapy. Nature, 411: 380-384. doi:10.1038/35077246.
20. Schweitzer, A.N., and Sharpe, A.H. 1998. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. J. Immunol. 161: 2762-2771.
21. Shen, W., Wang, Y., Geng, Y., and Si, L. 2000. Bacterially produced human B7-1 protein encompassing its complete extracellular domain maintains its costimulatory activity in vitro. Chin. Med. J. (Engl.), 113: 714-719.
22. Syme, R., and Gluck, S. 2001. Generation of dendritic cells: role of cytokines and potential clinical applications. Transfus. Apher. Sci. 24: 117-124. doi:10.1016/S1473-0502(01)00005-2.
23. Teng, M.N., Park, B.H., Koeppen, H.K., Tracey, K.J., Fendly, B.M., and Schreiber, H. 1991. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc. Natl. Acad. Sci. U.S.A. 88: 3535-3539. doi:10.1073/pnas.88.9.3535.
24. Tepper, R.I., Pattengale, P.K., and Leder, P. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell, 57: 503-512. doi:10.1016/0092-8674(89)90925-2.
25. Watanabe, Y., Kuribayashi, K., Miyatake, S., Nishihara, K., Nakayama, E., Taniyama, T., and Sakata, T. 1989. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 86: 9456-9460. doi:10.1073/pnas.86.23.9456.